【摘要】：當(dāng)前治療抑郁癥的主流藥物有選擇性5羥色胺(5-HT)攝取抑制劑(SSRIs)和5-HT、去甲腎上腺素(NE)雙重再攝取抑制劑(SNRIs);臨床使用過(guò)程中存在起效緩慢、快感缺乏、認(rèn)知功能低下和性功能障礙等缺陷;臨床前和臨床研究顯示,在SNRIs的基礎(chǔ)上加入多巴胺(DA)攝取抑制的5-HT/NE/DA三重再攝取抑制劑(SNDRIs)能夠改善目前藥物存在的治療缺陷。鹽酸安舒法辛為一種全新的SNDRIs,通過(guò)不均衡抑制5-HT/NE/DA再攝取發(fā)揮抗抑郁作用,預(yù)期在臨床應(yīng)用上將具有起效快,改善患者快感缺乏和性功能障礙,增加認(rèn)知、獎(jiǎng)勵(lì)激勵(lì)驅(qū)動(dòng)和目標(biāo)導(dǎo)向行為等特點(diǎn)。
[Abstract]:The current mainstream drugs in the treatment of depression include selective serotonin (5-HT) uptake inhibitors (SSRIs) and 5-HTand norepinephrine (NE) dual reuptake inhibitor (SNRIs); There are some defects in clinical use, such as slow onset, lack of pleasure, low cognitive function and sexual dysfunction. Pre-clinical and clinical studies have shown that the addition of (SNDRIs), a triple reuptake inhibitor of 5-HT/NE/DA with dopamine (DA) uptake inhibition on the basis of SNRIs, can improve the current treatment defects. The antidepressant effect of ambrofaxine hydrochloride is a new kind of SNDRIs, which plays an antidepressant role through unbalanced inhibition of 5-HT/NE/DA reuptake. It is expected that it will take effect quickly in clinical application, improve the patients' pleasure deficiency and sexual dysfunction, and increase cognition. Incentive-driven and goal-oriented behavior and so on.
【作者單位】： 煙臺(tái)大學(xué)藥學(xué)院分子藥理和藥物評(píng)價(jià)省部共建教育部重點(diǎn)實(shí)驗(yàn)室;綠葉制藥集團(tuán)長(zhǎng)效緩控釋和靶向制劑企業(yè)國(guó)家重點(diǎn)實(shí)驗(yàn)室;
【基金】：國(guó)家“重大新藥創(chuàng)制”科技重大專項(xiàng)(2013ZX09402201)
【分類號(hào)】：R749.4

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 栗原雅直;葉惠珍;;抗抑郁藥[J];國(guó)外醫(yī)藥.合成藥.生化藥.制劑分冊(cè);1986年03期

，

本文編號(hào)：2389254